Overview of the Global Vaccination against Human Papillomavirus
Leyla S. Namazova-Baranova,
Daria S. Chemakina,
Elena A. Vishneva,
Marina V. Fedoseenko,
Lilia R. Selimzianova https://doi.org/10.15690/pf.v15i1.1846
Abstract
The article presents an overview of the current status of the vaccination against Human Papillomavirus (HPV) in the world. It describes different approaches to expanding the coverage with HPV vaccination at different national levels by inclusion of the vaccine in National Immunization Programmes. Moreover, the principal ways of project financing in different regions of the world are referred to. The results of the implemented vaccination against HPV in the pioneer countries provide the conclusions on the current situation of HPV vaccination in the world and strategies demonstrating its effectiveness.
About the Authors
Leyla S. Namazova-Baranova
National Medical Research Center of Children’s Health; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
Daria S. Chemakina
National Medical Research Center of Children’s Health; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Moscow
Elena A. Vishneva
National Medical Research Center of Children’s Health
Russian Federation
Russian Federation
Moscow
Marina V. Fedoseenko
National Medical Research Center of Children’s Health;
Russian Federation
Russian Federation
Moscow
Lilia R. Selimzianova
National Medical Research Center of Children’s Health; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. msfaccess.org [Internet]. Médecins Sans Frontières [Doctors without borders]. Human Papillomavirus Vaccines (HPV) WHO recommendations & general information. 2014. [cited 2017 Jun 13]. Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/Vaccines/Docs/VAC_report_ProductCardHPV_ENG_2014.pdf
2. who.int [Internet]. WHO vaccine-preventable diseases: monitoring system. 2017 global summary [cited 2017 Jun 13]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules
3. Региональные бюро ВОЗ. [WHO regional offices. (In Russ).] Доступно по: http://www.who.int/about/regions/ru/ Ссылка активна на 29.09.2017.
4. Альянс ГАВИ. ВОЗ. [GAVI Alliance. (In Russ).] Доступно по: http://www.euro.who.int/ru/about-us/partners/global-healthpartnerships/gavi-alliance. Ссылка активна на 29.09.2017.
5. gavi.org [Internet]. GAVI: The Vaccine Alliance. Country Hub [cited 2017 Aug 9]. Available from: http://www.gavi.org/country/
6. gavi.org [Internet]. GAVI: The Vaccine Alliance. HPV. Countries approved for support 2017 [cited 2017 Aug 9]. Available from: http://www.gavi.org/results/countries-approved-for-support/
7. Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer. 2016;139(3):518–526. doi: 10.1002/ijc.30092.
8. Ngabo F, Franceschi S, Baussano I, et al. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2016;16:225. doi: 10.1186/s12879-016-1539-6.
9. Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Rwanda [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/RWA.pdf
10. UNICEF Supply Division. Human Papillomavirus Vaccine Supply & Demand Update. 2015 [Internet]. [cited 2017 Aug 10]. Available from: https://www.unicef.org/supply/files/Human_Papillomavirus_Vaccine(HPV)_Supply_and_Demand_Update_-_July_2015.pdf
11. nci.nih.gov [Internet]. President’s cancer panel annual report. Part 4. Increasing global HPV vaccination*. 2013 [cited 2017 Aug 10]. Available from: https://deainfo.nci.nih.gov/advisory/pcp/annualreports/hpv/Part4.htm#ref16
12. paho.org [Internet]. About the Pan American Health Organization (PAHO) [cited 2017 Aug 10]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=91&Itemid=220&lang=en
13. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):E1131–E1140. doi: 10.1542/peds.2014-2961.
14. Kim J, Bell C, Sun MG, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281–E288. doi: 10.1503/cmaj.151528.
15. Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015;137(8):1931–1937. doi: 10.1002/ijc.29508.
16. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393. doi: 10.1093/infdis/jit192.
17. Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States 2008–2012. Vaccine. 2015;33(13):1608–1613. doi: 10.1016/j.vaccine.2015.01.084.
18. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109–113. doi: 10.1016/j.vaccine.2012.10.092.
19. Hariri S, Unger ER, Powell SE, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2012;23(2):281–288. doi: 10.1007/s10552-011-9877-6.
20. Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human
21. Papillomavirus and Related Diseases in Libya [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/LBY.pdf.
22. Ben Khaial F, Bodalal Z, Elramli A, et al. Cervical cancer in northeastern Libya: 2000–2008. J Obstet Gynaecol. 2014;34(6):523–526. doi: 10.3109/01443615.2014.914478.
23. Hussein WM, Anwar WA, Attaleb M, et al. A review of the infection-associated cancers in North African countries. Infect Agent Cancer. 2016;11:35. doi: 10.1186/s13027-016-0083-8.
24. Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Bahrain [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/BHR.pdf
25. Hajjaj AA, Senok AC, Al-Mahmeed AE, et al. Human papillomavirus infection among women attending health facilities in the Kingdom of Bahrain. Saudi Med J. 2006;27(4):487–491.
26. Moosa K, Alsayyad AS, Quint W, et al. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014;14:905. doi: 10.1186/1471-2407-14-905.
27. Bhatia R, Kavanagh K, Cubie HA, et al. Use of HPV testing for cervical screening in vaccinated womenInsights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer. 2016;138(12):2922–2931. doi: 10.1002/ijc.30030.
28. Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.
29. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–1830. doi: 10.1038/bjc.2014.479.
30. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125–128. doi: 10.1136/sextrans-2016-052626.
31. Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018. [Epub ahead of print] doi: 10.1002/ijc.31231.
32. Tshomo U, Franceschi S, Dorji D, et al. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2014;14(1):408. doi: 10.1186/1471-2334-14-408.
33. Osborne SL, Tabrizi SN, Brotherton JML, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33(1):201–208. doi: 10.1016/j.vaccine.2014.10.045.
34. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032.
35. Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527. doi: 10.1093/cid/ciw354.
36. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a populationbased HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. doi: 10.1186/1741-7015- 11-227.
37. Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccinetargeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17(1):68–77. doi: 10.1016/S1473-3099(16)30116-5.
38. Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual males following a National Female Vaccination Program. J Infect Dis. 2016;215(2):202–208. doi: 10.1093/infdis/jiw530.
Review
For citations:
Namazova-Baranova L.S., Chemakina D.S., Vishneva E.A., Fedoseenko M.V., Selimzianova L.R. Overview of the Global Vaccination against Human Papillomavirus. Pediatric pharmacology. 2018;15(1):80-85. (In Russ.) https://doi.org/10.15690/pf.v15i1.1846
Views:
1259
Email this article 